ArticleBMC musculoskeletal disorders2026
Multifunctional MoS₂-PMMA bone cement with enhanced strength and antibacterial activity to overcome limitations of conventional materials in orthopedic surgery.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsThe increasing incidence of osteoporotic vertebral compression fractures (OVCFs) necessitates the development of effective treatment strategies. Polymethylmethacrylate (PMMA) bone cement, which is widely used, lacks adequate antimicrobial properties and poses the risk of postoperative infections. Molybdenum disulfide (MoS₂) nanosheets, which are known for their antimicrobial and osteogenic potential, offer a novel approach.
methodsWe synthesized PMMA-MoS₂ nanocomposites by incorporating MoS₂ nanosheets into PMMA bone cement. The mechanical properties of the composites were evaluated using tensile tests. Additionally, finite element analysis was conducted to simulate the stress distribution in the spine after vertebroplasty. Osteoblast viability, differentiation, and maturation were assessed using the CCK-8 assay, alkaline phosphatase (ALP) staining, and alizarin red S (ARS) staining. The antimicrobial activity was tested against Escherichia coli.
resultsPMMA-MoS₂ nanocomposites significantly increased elastic modulus from 2100.1 ± 29.7 to 2706.1 ± 14.7 MPa (P < 0.05) and tensile strength from 45.2 ± 2.1 to 56.9 ± 1.5 MPa at 5% MoS₂. Finite element models showed no significant alterations in stress distribution patterns on the adjacent vertebral surfaces, indicating mechanical stability. As assessed by CCK-8 assays, the presence of MoS₂ led to a marked increase in osteoblast proliferation, with cell viability consistently exceeding 100% at all time points. ALP staining demonstrated a concentration-dependent enhancement in osteoblast differentiation, with the PMMA + 5%MoS₂ composite showing the highest ALP activity. Moreover, the ARS-stained area expanded as the MoS₂ concentration increased, indicating a pronounced increase in the formation of mineralized nodules. Antimicrobial testing confirmed that the PMMA-MoS₂ composites substantially reduced Escherichia coli counts, with the PMMA + 5%MoS₂ composite exhibiting the most potent effect.
conclusionsThis study demonstrates that PMMA-MoS₂ nanocomposites offer improved mechanical, osteogenic, and antimicrobial properties, presenting a promising material for orthopedic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.